1185428-32-3

Basic information

• Product Name: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde
• Synonyms: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde;2-broMo-5h-pyrrolo[2,3-b]pyrazine-7-carbaldehyde
• CAS NO: 1185428-32-3
• Molecular Formula: C₇H₄BrN₃O
• Molecular Weight: 226.03016
• Mol File: 1185428-32-3.mol

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(1185428-32-3)
• EPA Substance Registry System: 2-BroMo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde(1185428-32-3)

Safety Data

• Hazardous Substances Data: 1185428-32-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it a candidate for the development of new drugs or drug candidates, particularly in the area of medicinal chemistry where novel scaffolds are constantly sought after for potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde may be employed as a reagent in various chemical reactions. Its specific functional groups and structural features could be leveraged to facilitate targeted chemical transformations or to produce specific types of compounds that are otherwise difficult to synthesize.
Given the limited information on its toxicity and environmental impact, it is crucial that any application of 2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxaldehyde is conducted with appropriate safety measures and professional oversight to ensure responsible use and minimize potential risks.

Upstream product

• 875781-43-4 2-bromo-5H-pyrrolo[2,3-b]pyrazine 
• 100-97-0 hexamethylenetetramine 
• 875781-41-2 5-bromo-3-((trimethylsilyl)ethynyl)pyrazine-2-amine 
• 76-05-1 trifluoroacetic acid 
• 1334674-88-2 (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 
• 1334674-87-1 (2-bromo-5-hydroxymethyl-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol 

Downstream Products

• 1185428-34-5 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo-[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-22-7 2-phenoxy-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-23-8 2-phenoxy-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid 
• 1334674-52-0 2-[1-(2,5-Difluoro-phenyl)-1H-imidazol-4-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]amide 
• 1334675-75-0 2-[1-(2,5-difluoro-phenyl)-1H-imidazol-4-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde 
• 1334675-76-1 2-[1-(2,5-difluoro-phenyl)-1H-imidazol-4-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid 
• 1334673-38-9 2-phenoxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-methyl-1-(pyrrolidine-1-carbonyl)propyl]amide 
• 1334673-85-6 2-cyclopropyl-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxy-4-phenylpiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334674-10-0 2-cyclohexyloxy-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanopiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334674-79-1 2-(2-methyl-1-phenyl-1H-imidazol-4-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 
• 1334674-80-4 2-(4-trifluoromethylphenyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 
• 1334675-19-2 2-cyclopropyl-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxy-4-phenylpiperidine-1-carbonyl)-2,2-dimethylpropyl]amide 
• 1334675-24-9 2-phenoxy-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-methyl-1-(pyrrolidine-1-carbonyl)propyl]amide 
• 1334675-71-6 2-(2-methyl-1-phenyl-1H-imidazol-4-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyanoazetidin-1-yl)-1-cyclopropyl-2-oxoethyl]amide 

Relevant articles and documents

3-amido pyrrolopyrazine JAK kinase inhibitors: Development of a JAK3 vs JAK1 selective inhibitor and evaluation in cellular and in vivo models

The Janus kinases (JAKs) are involved in multiple signaling networks relevant to inflammatory diseases, and inhibition of one or more members of this class may modulate disease activity or progression. We optimized a new inhibitor scaffold, 3-amido-5-cycl

PYRROLOPYRIMIDINE ITK INHIBITORS

Disclosed herein are arylpyridinone compounds and compositions useful in the treatment of ITK mediated diseases, such as inflammation, having the structures of Formulas (I)-(IV): wherein the R groups, m, n, and X are as defined in the detailed description. Methods of inhibition of ITK activity in a human or animal subject are also provided.

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL, PYRROLO[2,3-B]PYRIDINYL ACRYLAMIDES AND EPOXIDES THEREOF

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3- b]pyrazinyl,and pyrrolo[2,3-b]pyridinyl acrylamides, epoxides,and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention

PYRROLO[2,3-D]PYRIMIDINYL, PYRROLO[2,3-B]PYRAZINYL AND PYR-ROLO[2,3-D]PYRIDINYL ACRYLAMIDES

The present invention provides pharmaceutically active pyrrolo[2,3-d]pyrimidinyl and pyrrolo[2,3-d]pyridinyl acrylamides and analogues thereof. Such compounds are useful for inhibiting Janus Kinase (JAK). This invention also is directed to compositions comprising methods for making such compounds, and methods for treating and preventing conditions mediated by JAK.

DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES

The present invention relates to certain diaryl macrocyclic compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

Its use as an inhibitor and JAK and SYK deriv. pyrroropyrazine

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables Q, R2, R3, and Y are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.

AZAINDOLE DERIVATIVES AS JAK3 INHIBITORS

The present disclosure provides compounds that are JAK3 inhibitors and therefore useful for the treatment of diseases treatable by inhibition of JAK3 such as cancer and inflammatory diseases. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS

The present invention relates to the use of novel pyrrolo[2,3- b]]pyrazines wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.

Pyrrolopyrazines as selective spleen tyrosine kinase inhibitors

We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies. Ultimately, our mouse model revealed unexpected toxicity that precluded us from further advancing this series.

PYRROLOPYRAZINE KINASE INHIBITORS

The present invention relates to the use of novel pyrrolopyrazine derivatives of Formula I, wherein the variables are defined as described herein, which inhibit JAK and SYK and are useful for the treatment of auto-immune and inflammatory diseases.